| Literature DB >> 34055529 |
Ali Bin Sarwar Zubairi1, Mosavir Ansarie2, Talha Mahmud3, Saadia Ashraf4, Nisar Ahmed Rao5, Arshad Javaid6, Zubair Shaheen7, Shereen Khan8, Afzaalullah Khan9.
Abstract
Introduction Interstitial lung disease (ILD) is a heterogeneous group of over 200 parenchymal lung diseases with a myriad of etiologies. Interstitial lung disease registries from around the world show varying prevalence and incidence of these diseases. The aim of this study was to determine the epidemiology and characteristics of ILD in Pakistan. Methods This web-based registry, which is the first multicenter registry of ILD from Pakistan, recruited patients from 10 centers of five major cities between January 2016 and March 2019. Results A total of 744 patients were enrolled in the registry. The five most frequent ILDs were idiopathic pulmonary fibrosis (IPF) 34.4%, hypersensitivity pneumonitis (HP) - 17.7%, idiopathic nonspecific interstitial pneumonitis (iNSIP) - 16.8%, connective tissue disease-associated ILD (CTD-ILD) - 16.3%, and sarcoidosis - 9.1%. Conclusion Idiopathic pulmonary fibrosis is the most prevalent ILD in Pakistan, followed by HP and iNSIP. An ongoing prospective registry with longitudinal follow-up will help us further elaborate on the clinical characteristics, treatment, and survival outcome of patients with ILD.Entities:
Keywords: interstitial lung disease; lung fibrosis; pulmonary fibrosis; rare lung diseases
Year: 2021 PMID: 34055529 PMCID: PMC8149777 DOI: 10.7759/cureus.14684
Source DB: PubMed Journal: Cureus ISSN: 2168-8184
Figure 1Recruitment from Different Centres of Pakistan
AKUH=Aga Khan University Hospital, DP=Doctors Plaza, DUHS=Dow University of Health Sciences, SZH=Sheikh Zayed Hospital, KEMU=King Edward Medical University, NMCU=Nishtar Medical College, GDCH=Gulab Devi Chest Hospital, KTH=Khyber Teaching Hospital, LRH=Lady Reading Hospital, FJCGH=Fatema Jinnah Chest & General Hospital
Relative Frequencies of Interstitial Lung Diseases in ILD Registry
ILD=Interstitial Lung Disease, IPF=Idiopathic Pulmonary Fibrosis, HP=Hypersensitivity Pneumonitis, iNSIP=Idiopathic Nonspecific Interstitial Pnuemonitis, CTD-ILD=Connective Tissue Disease Associated ILD, CPFE=Combined Pulmonary Fibrosis with Emphysema, RA=Rheumatoid Arthritis, SD=Scleroderma, MCTD=Mixed Connective Tissue Disease, SLE=Systemic Lupus Erythematosus, PM/DM=Polymyositis/Dermatomyositis, SS=Sjögren's Syndrome, COP/BOOP=Cryptogenic Organizing Pneumonia/Bronchiolitis Obliterans Organizing Pneumonia, IPAF=Interstitial Pneumonia with Autoimmune Features, PAP=Pulmonary Alveolar Proteinosis, PLCH=Pulmonary Langerhans Cell Histiocytosis, LAM=Lymphangioleiomyomatosis, RB-ILD=Respiratory Bronchiolitis ILD, CWP= Coal Worker’s Pneumoconiosis, DIP=Desquamative Interstitial Pneumonia, AIP=Acute Interstitial Pneumonia, BO=Bronchiolitis Obliterans
| Types of ILD | n (n%) |
| IPF | 256 (34.4%) |
| CPFE | 11 (1.5%) |
| HP | 132 (17.7%) |
| iNSIP | 125 (16.8%) |
| CTD-ILD | 121 (16.3%) |
| RA | 56 (7.5%) |
| SD | 25 (3.4%) |
| MCTD | 14 (1.9%) |
| SLE | 13 (1.7%) |
| PM/DM | 11 (1.5%) |
| SS | 2 (0.3%) |
| Sarcoidosis | 68 (9.1%) |
| Others | 42 (5.7%) |
| COP/BOOP | 15 (2%) |
| Drug Induced ILD | 6 (0.8%) |
| Methotrexate | 3 (0.4%) |
| Cyclophosphamide | 2 (0.3%) |
| Interferon | 1 (0.1%) |
| IPAF | 5 (0.7%) |
| PAP | 3 (0.4%) |
| PLCH | 2 (0.3%) |
| LAM | 2 (0.3%) |
| RB-ILD | 2 (0.3%) |
| Silicosis | 2 (0.3%) |
| CWP | 1 (0.1%) |
| DIP | 1 (0.1%) |
| AIP | 1 (0.1%) |
| BO | 1 (0.1%) |
| Undetermined ILD | 1 (0.1%) |
Demographics and Clinical Features of ILD
ILD=Interstitial Lung Disease, IPF=Idiopathic Pulmonary Fibrosis, UIP=Usual Interstitial Pneumonia, HP=Hypersensitivity Pneumonitis, iNSIP=Idiopathic Nonspecific Interstitial Pnuemonitis, CTD-ILD=Connective Tissue Disease Associated ILD, COPD=Chronic Obstructive Pulmonary Disease, GERD=Gastroesophageal Reflux Disease, PAH=Pulmonary Arterial Hypertension, mPAP=Mean Pulmonary Arterial Pressure
| Overall (n=744) | IPF/UIP (n= 256) | HP (n=132) | iNSIP (n=125) | CTD-ILD (n=121) | Sarcoidosis (n=68) | Others (n=42) | P-value | |
| Age in years; mean ±SD | 56.2 ±13.9 | 64.5 ±11.8 | 51.6 ±13.5 | 55.4 ±11.7 | 50.3 ±12.1 | 50.3 ±12.7 | 48.4 ±15.5 | ˂0.001 |
| Gender; n (%) | ˂0.001 | |||||||
| Male | 256 (34.4%) | 139 (54.3%) | 34 (25.8%) | 23 (18.4%) | 12 (9.9%) | 23 (33.8%) | 25 (59.5%) | |
| Female | 488 (65.6%) | 117 (45.7%) | 98 (74.2%) | 102 (81.6%) | 109 (90.1%) | 45 (66.2%) | 17 (40.5%) | |
| Area of Living; n (%) | 0.023 | |||||||
| Rural | 65 (8.7%) | 32 (12.5%) | 8 (6.1%) | 15 (12%) | 5 (4.1%) | 3 (4.4%) | 2 (4.8%) | |
| Urban | 679 (91.3%) | 224 (87.5%) | 124 (93.9%) | 110 (88%) | 116 (95.9%) | 65 (95.6%) | 40 (95.2%) | |
| Smoking History; n (%) | 113 (15.2%) | 67 (26.2%) | 9 (6.8%) | 9 (7.2%) | 8 (6.6%) | 5 (7.4%) | 15 (35.7%) | ˂0.001 |
| Clubbing; n (%) | 247 (33.2%) | 121 (47.3%) | 43 (32.6%) | 37 (29.6%) | 30 (24.8%) | 8 (11.8%) | 8 (19%) | ˂0.001 |
| Hypertension; n (%) | 288 (38.7%) | 112 (43.8%) | 40 (30.3%) | 59 (47.2%) | 46 (38%) | 23 (33.8%) | 8 (19%) | 0.003 |
| Diabetes Mellitus; n (%) | 215 (28.9%) | 72 (28.1%) | 37 (28%) | 53 (42.4%) | 24 (19.8%) | 21 (30.9%) | 8 (19%) | 0.003 |
| COPD; n (%) | 48 (6.5%) | 30 (11.7%) | 3 (2.3%) | 6 (4.8%) | 2 (1.7%) | 3 (4.4%) | 4 (9.5%) | 0.001 |
| GERD; n (%) | 195 (26.2%) | 77 (30.1%) | 35 (26.5%) | 39 (31.2%) | 29 (24%) | 8 (11.8%) | 7 (16.7%) | 0.021 |
| Echocardiography; n (%) | 432 (58.1%) | 149 (58.2%) | 86 (65.2%) | 76 (60.8%) | 78 (64.5%) | 22 (32.4%) | 21 (50%) | ˂0.001 |
| PAH (n=432); n (%) | 206 (47.7%) | 77 (51.7%) | 39 (45.3%) | 46 (60.5%) | 29 (37.2%) | 9 (40.9%) | 6 (28.6%) | 0.023 |
| Severity of PAH (mPAP) (n=206); n (%) | 0.508 | |||||||
| Mild (25 – 40 mmHg) | 92 (44.7%) | 37 (48.1%) | 17 (43.6%) | 22 (47.8%) | 9 (31%) | 4 (44.4%) | 3 (50%) | |
| Moderate (41 – 55 mmHg) | 62 (30.1%) | 19 (24.7%) | 15 (38.5%) | 13 (28.3%) | 13 (44.8%) | 1 (11.1%) | 4 (44.4%) | |
| Severe (> 55 mmHg) | 52 (25.2%) | 21 (27.3%) | 7 (17.9%) | 11 (23.9%) | 7 (24.1%) | 4 (44.4%) | 2 (33.3%) | |
Figure 2Gender-wise Exposure in Patients with Hypersensitivity Pneumonitis
Figure 3Box and Whisker Plot of Forced Vital Capacity (% of predicted) in Different ILDs
FVC=Forced Vital Capacity, ILD=Interstitial Lung Disease